Melittin restores PTEN expression by down-regulating HDAC2 in human hepatocelluar carcinoma HepG2 cells

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Zhang, Hui ^a   Zhao, Bin ^a   Huang, Cheng ^a   Meng, Xiao Ming ^a   Bian, Er Bao ^a   Li, Jun ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; HISTONE DEACETYLASE 2; MELITTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PTEN PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SEQUENCE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MITOSIS INHIBITION; NUCLEOTIDE SEQUENCE; PTEN GENE; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY;

CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; DOWN-REGULATION; HEP G2 CELLS; HISTONE DEACETYLASE 2; HUMANS; LIVER NEOPLASMS; MELITTEN; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84900444354     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095520     Document Type: Article

References (38)

1. Ahn S, Hyeon J, Park CK (2013) Metadherin is a prognostic predictor of hepatocellular carcinoma after curative hepatectomy. Gut Liver 7: 206-212.
2. El-Serag HB, Rudolph KL (2007) Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology 132: 2557-2576. (Pubitemid 46890874)
3. Maluccio M, Covey A (2012) Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 62: 394-399.
4. Gan YH, Zhang S (2009) PTEN/AKT pathway involved in histone deacetylases inhibitor induced cell growth inhibition and apoptosis of oral squamous cell carcinoma cells. Oral Oncology 45: e150-e154.
5. Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the PTEN tumour suppressor. Nature Reviews Molecular Cell Biology.
6. Bian EB, Huang C, Ma TT, Tao H, Zhang H, et al. (2012) DNMT1-mediated PTEN hypermethylation confers hepatic stellate cell activation and liver fibrogenesis in rats. Toxicol Appl Pharmacol 264: 13-22.
7. Huang WJ, Lin CW, Lee CY, Chi LL, Chao Y-C, et al. (2011) NBM-HD-3, a novel histone deacetylase inhibitor with anticancer activity through modulation of PTEN and AKT in brain cancer cells. Journal of Ethnopharmacology 136: 156-167.
8. Noro R, Gemma A, Miyanaga A, Kosaihira S, Minegishi Y, et al. (2007) PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Oncol 31: 1157-1163.
9. Oiso H, Furukawa N, Suefuji M, Shimoda S, Ito A, et al. (2011) The role of class I histone deacetylase (HDAC) on gluconeogenesis in liver. Biochemical and Biophysical Research Communications 404: 166-172.
10. Barneda-Zahonero B, Parra M (2012) Histone deacetylases and cancer. Molecular Oncology 6: 579-589.
11. Jeong JB, Lee SH (2013) Protocatechualdehyde possesses anti-cancer activity through downregulating cyclin D1 and HDAC2 in human colorectal cancer cells. Biochemical and Biophysical Research Communications 430: 381-386.
12. Morine Y, Shimada M, Iwahashi S, Utsunomiya T, Imura S, et al. (2012) Role of histone deacetylase expression in intrahepatic cholangiocarcinoma. Surgery 151: 412-419.
13. Regel I, Merkl L, Friedrich T, Burgermeister E, Zimmermann W, et al. (2012) Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2. Gastroenterology 143: 99-109 e110.
14. Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, et al. (2012) Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol 56: 1343-1350.
15. Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, et al. (2007) Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 46: 1119-1130. (Pubitemid 350144776)
16. Liu S, Yu M, He Y, Xiao L, Wang F, et al. (2008) Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway. Hepatology 47: 1964-1973. (Pubitemid 351945563)
17. Lee WR, Park JH, Kim KH, Park YY, Han SM, et al. (2011) Protective effects of melittin on transforming growth factor-beta1 injury to hepatocytes via antiapoptotic mechanism. Toxicol Appl Pharmacol 256: 209-215.
18. Zhu X, Qin X, Fei M, Hou W, Greshock J, et al. (2013) Loss and reduced expression of PTEN correlate with advanced-stage gastric carcinoma. Exp Ther Med 5: 57-64.
19. Moon SH, Kim DK, Cha Y, Jeon I, Song J, et al. (2013) PI3K/Akt and Stat3 signaling regulated by PTEN control of the cancer stem cell population, proliferation and senescence in a glioblastoma cell line. Int J Oncol 42: 921-928.
20. Kwak MK, Johnson DT, Zhu C, Lee SH, Ye DW, et al. (2013) Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors. PLoS ONE 8: e53476.
21. Peyrou M, Bourgoin L, Foti M (2010) PTEN in liver diseases and cancer. World J Gastroenterol 16: 4627-4633.
22. Wikman H, Lamszus K, Detels N, Uslar L, Wrage M, et al. (2012) Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res 14: R49.
23. Li QL, Gu FM, Wang Z, Jiang JH, Yao LQ, et al. (2012) Activation of PI3K/AKT and MAPK pathway through a PDGFRbeta-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma. PLoS ONE 7: e33379.
24. Correia NC, Girio A, Antunes I, Martins LR, Barata JT (2014) The multiple layers of non-genetic regulation of PTEN tumour suppressor activity. Eur J Cancer 50: 216-225.
25. Ikenoue T, Inoki K, Zhao B, Guan KL (2008) PTEN acetylation modulates its interaction with PDZ domain. Cancer Res 68: 6908-6912.
26. Sakamoto K, Iwasaki K, Sugiyama H, Tsuji Y (2009) Role of the Tumor Suppressor PTEN in Antioxidant Responsive Element-mediated Transcription and Associated Histone Modifications. Molecular Biology of the Cell 20: 1606-1617.
27. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50.
28. Icardi L, De Bosscher K, Tavernier J (2012) The HAT/HDAC interplay: multilevel control of STAT signaling. Cytokine Growth Factor Rev 23: 283-291.
29. Witt O, Deubzer HE, Milde T and Oehme I (2009) HDAC family: What are the cancer relevant targets? Cancer Lett 277: 8-21.
30. Weichert W (2009) HDAC expression and clinical prognosis in human malignancies. Cancer Lett 280: 168-176.
31. Zhang L, Wang G, Wang L, Song C, Leng Y, et al. (2011) VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin. Molecular and Cellular Biochemistry 361: 39-45.
32. Kim JK, Noh JH, Eun JW, Jung KH, Bae HJ, et al. (2013) Targeted inactivation of HDAC2 restores p16INK4a activity and exerts antitumor effects on human gastric cancer. Mol Cancer Res 11: 62-73.
33. Wang G, Jiang X, Pu H, Zhang W, An C, et al. (2013) Scriptaid, a novel histone deacetylase inhibitor, protects against traumatic brain injury via modulation of PTEN and AKT pathway: scriptaid protects against TBI via AKT. Neurotherapeutics 10: 124-142.
34. Pan L, Lu J, Wang X, Han L, Zhang Y, et al. (2007) Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by upregulating PTEN expression. Cancer 109: 1676-1688. (Pubitemid 46595705)
35. Luo L, Gong YQ, Qi X, Lai W, Lan H, et al. (2013) Effect of tumor suppressor PTEN gene on apoptosis and cell cycle of human airway smooth muscle cells. Mol Cell Biochem 375: 1-9.
36. Moon DO, Park SY, Choi YH, Kim ND, Lee C, et al. (2008) Melittin induces Bcl-2 and caspase-3-dependent apoptosis through downregulation of Akt phosphorylation in human leukemic U937 cells. Toxicon 51: 112-120.
37. Lin CC, Zhou JP, Liu YP, Liu JJ, Yang XN, et al. (2012) The silencing of Pokemon attenuates the proliferation of hepatocellular carcinoma cells in vitro and in vivo by inhibiting the PI3K/Akt pathway. PLoS ONE 7: e51916.
38. Roy SK, Srivastava RK, Shankar S (2010) Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 5: 10.